Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Yale
•
Triple negative
•
NCI-CCC Breast Tumor Board Question
How would you manage patients with TNBC who achieve a pCR with neoadjuvant KEYNOTE-522 regimen, but develop isolated chest wall recurrence soon after completing neoadjuvant treatment?
Would you provide adjuvant therapy? Palliative therapy?
No evidence of distance metastases.
Related Questions
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
What initial treatment would you offer a patient with metastatic triple negative breast cancer with somatic BRCA1/2 mutation, CPS <10?
How would you approach the treatment of low grade, stage IA, triple negative apocrine adenocarcinoma of the breast in a female patient in her 70s?
How would you treat a young premenopausal female with triple negative inflammatory breast cancer who progressed on carboplatin/paclitaxel/pembrolizumab (KEYNOTE 522), but didn't receive anthracycline portion and has a positive BRCA2 mutation?
Would you offer adjuvant chemotherapy for triple negative invasive papillary carcinoma of breast?
Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?
Do you use elacestrant for all patients with metastatic ER+, HER2-, ESR1 mutated breast cancer regardless of duration of response to prior ET+CDK4/6i?
What is your management approach for CAR-T induced motor neurologic deficits (cyclophosphamide/IVIG/Steroids, etc) and any prophylactic approach to an early, rapid rise in absolute lymphocyte count post CAR-T infusion?
In what circumstance, if any, would you consider fulvestrant + capivasertib over CDK4/6 inhibitors in a patient who has HR+, PIK3CA mutant metastatic breast cancer?